Steven Deeks, MD

Headshot of Steven Deeks
User Profile Photo

Steven Deeks, MD

User Profile Name
Co-Director, Clinical Core
Professor, School of Medicine
User Profile Title
User Profile Email
Visit CTSI Profile

Biography

Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment. He is also now leading a large program focused on the pathogenesis and treatment of Long COVID.

Dr. Deeks has published over 650 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants and is the contact principal investigator of DARE (the Delaney AIDS Research Enterprise), an NIH-funded international collaboration aimed at developing therapeutic interventions to cure HIV infection. He recently directed the amfAR Institute for HIV Cure Research. In early 2020, he leveraged his HIV research program to construct the “Long-term Impact of Infection with Novel Coronavirus (LIINC)” cohort, which is now supporting dozens of studies addressing the impact of SARS-CoV-2 on health.

Dr. Deeks is a member of the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP). He serves on the scientific advisory board for Science Translational Medicine and is the editor-in-chief of Current Opinion in HIV and AIDS. Based on a recent study conducted at Stanford, he is among the top 0.01% of all scientists, based on citations, adjusted for authorship position and impact, and has been listed by Clarivite as one of the world's most cited scientists for the past several years. In 2022, he received the Lifetime Achievement in Mentoring Award from UCSF.

In addition to his translational and clinical. investigation, Dr. Deeks maintains a primary care clinic for people living with HIV.

User Profile Bio

Displaying 426 - 450 of 668

  1. Papasavvas E, Hsue P, Reynolds G, Pistilli M, Hancock A, Martin JN, Deeks SG, Montaner LJ. Increased CD34+/KDR+ cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects. Antivir Ther. 2012; 17(3):557-63.
    http://www.ncbi.nlm.nih.gov/pubmed/22300770
  2. Deepe RN, Kistner-Griffin E, Martin JN, Deeks SG, Pandey JP. Epistatic interactions between Fc (GM) and FcγR genes and the host control of human immunodeficiency virus replication. Hum Immunol. 2012 Mar; 73(3):263-6.
    http://www.ncbi.nlm.nih.gov/pubmed/22213007
  3. Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol. 2012 Mar 01; 109(5):742-7.
    http://www.ncbi.nlm.nih.gov/pubmed/22169125
  4. Eriksson EM, Milush JM, Ho EL, Batista MD, Holditch SJ, Keh CE, Norris PJ, Keating SM, Deeks SG, Hunt PW, Martin JN, Rosenberg MG, Hecht FM, Nixon DF. Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood. 2012 Jan 19; 119(3):745-55.
    http://www.ncbi.nlm.nih.gov/pubmed/22134167
  5. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, Martin JN. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011 Nov 13; 25(17):2123-31.
    http://www.ncbi.nlm.nih.gov/pubmed/21881481
  6. Seu L, Burt TD, Witte JS, Martin JN, Deeks SG, McCune JM. Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. Genes Immun. 2012 Apr; 13(3):258-67.
    http://www.ncbi.nlm.nih.gov/pubmed/22048453
  7. Sips M, Sciaranghella G, Diefenbach T, Dugast AS, Berger CT, Liu Q, Kwon D, Ghebremichael M, Estes JD, Carrington M, Martin JN, Deeks SG, Hunt PW, Alter G. Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol. 2012 Jan; 5(1):30-40.
    http://www.ncbi.nlm.nih.gov/pubmed/21993602
  8. Geng EH, Kahn JS, Chang OC, Hare CB, Christopoulos KA, Jones D, Petersen ML, Deeks SG, Havlir DV, Gandhi M. The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clin Infect Dis. 2011 Nov; 53(10):1008-14.
    http://www.ncbi.nlm.nih.gov/pubmed/21960715
  9. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses. 2012 May; 28(5):469-77.
    http://www.ncbi.nlm.nih.gov/pubmed/21854232
  10. Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, Keller M, Grubeck-Loebenstein B, Simon A, Lambotte O, Hunt PW, Deeks SG, Costagliola D, Autran B, Sauce D. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011 Sep 24; 25(15):1813-22.
    http://www.ncbi.nlm.nih.gov/pubmed/21412126
  11. Rajasuriar R, Booth DR, Gouillou M, Spelman T, James I, Solomon A, Chua K, Stewart G, Deeks S, Bangsberg DR, Muzoora C, Cameron PU, Hunt P, Martin J, Lewin SR. The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. Genes Immun. 2012 Jan; 13(1):83-93.
    http://www.ncbi.nlm.nih.gov/pubmed/21938017
  12. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epi . Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15; 204(6):893-901.
    http://www.ncbi.nlm.nih.gov/pubmed/21849286
  13. Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, Kitahata MM, Willig JH, Moore RD, Deeks SG, Saag MS, Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Study . Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis. 2011 Nov; 53(9):927-35.
    http://www.ncbi.nlm.nih.gov/pubmed/21890751
  14. Deeks SG. HIV: How to escape treatment. Nature. 2011 Aug 31; 477(7362):36-7.
    http://www.ncbi.nlm.nih.gov/pubmed/21886150
  15. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011 Nov; 85(21):11422-34.
    http://www.ncbi.nlm.nih.gov/pubmed/21880771
  16. Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic D . Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35.
    http://www.ncbi.nlm.nih.gov/pubmed/21813792
  17. Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis. 2011 Aug 02; 11:208.
    http://www.ncbi.nlm.nih.gov/pubmed/21810243
  18. Geng EH, Glidden DV, Bwana MB, Musinguzi N, Emenyonu N, Muyindike W, Christopoulos KA, Neilands TB, Yiannoutsos CT, Deeks SG, Bangsberg DR, Martin JN. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One. 2011; 6(7):e21797.
    http://www.ncbi.nlm.nih.gov/pubmed/21818265
  19. Perelson AS, Deeks SG. Drug effectiveness explained: the mathematics of antiviral agents for HIV. Sci Transl Med. 2011 Jul 13; 3(91):91ps30.
    http://www.ncbi.nlm.nih.gov/pubmed/21753120
  20. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011 Oct; 141(4):1220-30, 1230.e1-3.
    http://www.ncbi.nlm.nih.gov/pubmed/21726511
  21. Kitchen CM, Yeghiazarian L, Hoh R, McCune JM, Sinclair E, Martin JN, Deeks SG. Immune activation, CD4+ T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infection. PLoS One. 2011; 6(6):e21190.
    http://www.ncbi.nlm.nih.gov/pubmed/17707394
    http://www.ncbi.nlm.nih.gov/pubmed/21701594
  22. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011 Jun 19; 25(10):1289-98.
    http://www.ncbi.nlm.nih.gov/pubmed/21516027
  23. Bacchetti P, Deeks SG, McCune JM. Breaking free of sample size dogma to perform innovative translational research. Sci Transl Med. 2011 Jun 15; 3(87):87ps24.
    http://www.ncbi.nlm.nih.gov/pubmed/21677197
  24. Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel-D, Rauch A, Ledergerber B, Deeks SG, Günthard HF, Wong JK, Pillai SK. Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol. 2014 Jan; 88(1):763-7.
    http://www.ncbi.nlm.nih.gov/pubmed/21633511
  25. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474-83.
    http://www.ncbi.nlm.nih.gov/pubmed/17117013
    http://www.ncbi.nlm.nih.gov/pubmed/21502083